Which drugs may be hit with ne­go­ti­a­tions if the rec­on­cil­i­a­tion bill pass­es? Wall St. an­a­lysts ex­plain

Be­yond the back and forth of whether De­moc­rats’ drug price ne­go­ti­a­tion plan is nec­es­sary to bring down costs, or just a thin­ly veiled at­tempt at price con­trols, the nuts and bolts of the deal mean phar­ma com­pa­nies will in­evitably see the tail ends of cer­tain small mol­e­cule and bi­o­log­ic sales pe­ter out be­fore they oth­er­wise would have in to­day’s mar­ket­place.

While the bill’s text is not set in stone, and the Sen­ate par­lia­men­tar­i­an may still take is­sue with the ex­cise tax that CMS will use to en­sure com­pa­nies com­ply with the ne­go­ti­at­ed prices, SVB Se­cu­ri­ties ex­plained to in­vestors how more than a dozen drugs from Eli Lil­ly, As­traZeneca, Ab­b­Vie and J&J, among oth­ers, would lose out on some rev­enue just be­fore their gener­ic com­peti­tors hit the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.